Listen
ZINFORO (ceftaroline), cephalosporin
INFECTIOUS MEDICINE- PAEDIATRICS - New indication
Opinions on drugs -
Posted on
Sep 06 2017
Reason for request
Extension of indication
Minor clinical added value in the management of complicated skin and soft tissue infectionsin children from the age of 2 months
Insufficient actual clinical benefit in community-acquired pneumonia due to the existence of therapeutic alternatives that are simpler to use and have a narrower therapeutic spectrum.
- ZINFORO now has Marketing Authorisation in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia in children from the age of 2 months
- Ceftaroline is a beta lactam of the third-generation cephalosporin family, with a broad spectrum, active on methicillin resistant Staphylococcus aureus (MRSA).
- ZINFORO can be proposed in complicated non-necrosing skin and soft tissue infections suspected or proven to be MRSA.
- It has no role in the therapeutic strategy for community-acquired pneumonia.
Clinical Benefit
| Substantial |
- |
| Insufficient |
Clinical Added Value
| minor |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
